Semaglutide reduces the risk of heart attack, stroke, and other major cardiac events. | Drug Discovery And Development ...

Even when weight doesn’t drop much, the obesity-medication semaglutide still offers major heart-protection, research shows.

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and ...

A new analysis finds that the heart-protecting benefits of semaglutide are largely independent of its weight loss effects.

The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...

Semaglutide appears to be protective against heart attacks and other cardiac events regardless of weight loss, research has ...

Novo Nordisk (($NVO)) announced an update on their ongoing clinical study. Study Overview: Novo Nordisk is conducting a study titled A Master ...

Please provide your email address to receive an email when new articles are posted on . Adults with overweight or obesity plus preexisting CVD had a reduction in CV event risk with semaglutide in ...

In a recent study published in Nature Medicine, researchers evaluated the efficacy of semaglutide in patients with the obesity phenotype of heart failure and preserved ejection fraction (HFpEF). Study ...

Semaglutide is at least as effective at preventing heart attacks and other cardiac events as well as death in people with impaired kidney function as it is in those with normal kidney function The ...

The use of semaglutide for non-diabetic obese patients with cardiovascular disease was first reported to be associated with significant benefit in the SELECT trial, where major adverse cardiovascular ...

PALM BEACH COUNTY, Fla. (CBS12) — Around 70% of American adults are overweight or clinically obese, according to the Food and Drug Administration (FDA). But these days fewer people are relying solely ...